Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Rb-Positive, Triple-Negative Metastatic Breast Cancer
NCT03130439Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in breast cancer, sponsored by Dana-Farber Cancer Institute. Started May 2017; status: terminated.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03130439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130439.